Routine Schedules for MenACWY and MenB Vaccines—Make Sure You’re Giving Them on Time

July 2017

Technically Speaking
Monthly Column by Deborah Wexler, MD
Deborah Wexler MD
Technically Speaking is a monthly column written by IAC’s Executive Director Deborah Wexler, MD. The column is featured in The Children’s Hospital of Philadelphia Vaccine Education Center’s (VEC’s) monthly e-newsletter for healthcare professionals. Technically Speaking columns cover practical topics in immunization delivery such as needle length, vaccine administration, cold chain, and immunization schedules.
Check out a recent issue of Vaccine Update for Healthcare Providers. The VEC e-newsletter keeps providers up to date on vaccine-related issues and includes reviews of recently published journal articles, media recaps, announcements about new resources, and a regularly updated calendar of events.
Routine Schedules for MenACWY and MenB Vaccines – Make Sure You’re Giving Them on Time
Published July 2017
At the Immunization Action Coalition (IAC), we receive many email questions from healthcare professionals each month indicating that there is confusion about the routine vaccination schedules for meningococcal conjugate (MenACWY) and meningococcal serogroup B (MenB) vaccines. What follows is simple guidance regarding CDC/AAP/AAFP/ACOG routine recommendations for the timing of administering these vaccines to your adolescent patients.

Important note: This brief summary article discusses only the routine schedule. It does not include catch-up schedules or recommendations for people in various risk groups.

Recommended schedules for routine vaccination

Meningococcal conjugate (MenACWY) vaccine
(Menactra®, Sanofi; Menveo®, GSK)

  • Dose #1: Age 11 to 12 years
  • Dose #2: Age 16 years

Unfortunately, most teens are behind on the 16-year-old dose of this two-dose series. According to the most recent CDC National Immunization Survey – Teen, only 33 percent of teens have received dose #2 before their 18th birthday.

Meningococcal serogroup B (MenB) vaccine
(Bexsero®, GSK; Trumenba®, Pfizer)

The preferred age range for routine* vaccination is 16 to 18 years, but MenB may be initiated up to age 25. Currently, there are two brands of MenB available in the United States:

Bexsero (GSK)

  • Dose #1: Age 16 to 18 years
  • Dose #2: > one month after dose #1

Trumenba (Pfizer)

  • Dose #1: Age 16 to 18 years
  • Dose #2: Six months after dose #1**

Note: These two vaccine brands are not interchangeable. The series must be started and completed with the same MenB brand.

*MenB vaccine is recommended by CDC as category B, which means that you can either give it routinely or that you can inform patients about the availability of this vaccine so they can decide in consultation with you if they want this protection.

**This article does not discuss the recommendation for including a third dose of Trumenba, which is recommended for people at high risk of meningococcal serogroup B infection. Refer to the CDC schedule for additional information for high-risk individuals.

Resources from IAC

Resources from CDC

This page was updated on .